🔎 Trials Near Me

Hjem › Leukemi › Alabama

Kliniske studier for Leukemi i Alabama

10 studier for Leukemi søker deltakere på steder i Alabama.

Byer i Alabama

Offisiell studietekst (engelsk)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 16, Birmingham
RekruttererFase 3
Alder 18 til 71 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07504458

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • University of Alabama - Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06824168

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

  • The University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07249346

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Birmingham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. jun. 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Hospital of Alabama, Birmingham
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT01790152

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 4. mar. 2026 · NCT07044544

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Birmingham
  • Massive Bio SYNERGY-AI site, Mobile
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. okt. 2025 · NCT06265584

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 60 · Alle kjønn · Oppdatert 8. okt. 2025 · NCT06315309

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. nov. 2024 · NCT06034275

Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.